Trial Profile
CHRONOS - A Multicenter, Non - Interventional Study to Observe the Safety and Efficacy of Vedolizumab (Entyvio) in Patients With Ulcerative Colitis or Crohn´s Disease That Are Biologic naïve, Observed in Daily Practice in Austria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2020
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHRONOS
- Sponsors Takeda
- 23 Sep 2020 Status changed from active, no longer recruiting to completed.
- 10 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Feb 2018 Planned End Date changed from 1 Nov 2018 to 31 Aug 2020.